Tailor-made Pharma Solutions l Pharma Intelligence

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Commercial Success

Clinical Planning

Patient Engagement & Recruitment

Regulatory & Compliance

Conferences 2022

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Tailor-made solutions

Use the expertise and experience of Pharma Intelligence to produce custom solutions that are actionable, flexible, and tailored to help you successfully navigate biopharma portfolio management, commercial optimization, and R&D strategy. Benefit from:

A customized approach – we develop solutions to fit your situation
Joint problem/opportunity definition
Proprietary data and complementary market research
The experience of 500+ industry experts
Collaborative problem solving
Fact-based decisions and actionable recommendations
Ownership of final decisions and action plans

Discover new business opportunities, reduce risks, and make better, faster decisions with tailor-made pharmaceutical solutions from Pharma Intelligence.

Scrip

Opdivos EU Colorectal Cancer is a Setback but More Than Offset By Potential Gains

By Ian Schofield 29 Nov 2022

Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.

Topic Cancer

View article
Trial Results Summaries

AstraZeneca takes an innovative approach to trial results summaries

25 Nov 2022

What Are Trial Results Summaries and Why Are They Necessary?

Topic Clinical Trials

View case study
Trial Results Summaries

Trial results transparency starts here

25 Nov 2022

Trial Results Summaries provides an unbiased and non-promotional portal for sponsors to share trial results summaries, also known as plain language summaries (PLS), with participants and the public.

Topic Clinical Trials

View case study
Citeline, Trialtrove

2020 Clinical Trials Roundup: Disruptions to the Trial Landscape

25 Nov 2022

Our annual analysis dissects the data of all Phase I–III clinical trials that started in a year dominated by COVID-19.

Topic Coronavirus

Full webinar
5 Top Tips For Generating Successful Content Marketing

18 Nov 2022

From choosing the right audience to measuring campaign results, follow these 5 tips when planning your successful content marketing campaign.

Advertising, Marketing & Sales

View infographic
In Vivo

Bayer’s US Playbook: The Smart Way To Top-Line Growth

By William Looney 14 Nov 2022

The hotly contested US market is central to Bayer’s aspirations to become a global innovation player in pharmaceuticals, especially in key growth segments like oncology. A little more than one year in, Bayer Pharmaceuticals Americas President Dr. Carsten Brunn reflects on his unit’s progress.

Topic Business Strategies Company Analysis

View article
Medtech Insight

Inside Toyota's 'Cult' Car-Makers Quality VP Tells Device-Makers How To Adopt 4-Pronged Quality Strategy

By Shawn M. Schmitt 14 Nov 2022

Toyota Motor North America's Kristen Tabar told a roomful of medical device quality and regulatory professionals at a Case for Quality forum that they can infuse quality concepts into every nook and cranny of their firms by adopting the car-maker's quality strategy of reflection, education, celebration and planning. "I don’t want to make it sound like it’s sort of cult-y, but it’s kind of cult-y," Tabar quipped.

Topic Company Analysis Strategy

View article
Scrip

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

By Jessica Merrill 14 Nov 2022

The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.

Topic Coronavirus Vaccines Sales Earnings

View article
Datamonitor Healthcare

Multiple Myeloma Pricing, Reimbursement, and Access

14 Nov 2022

Disease management and treatment programmes change, as research evolves and new discoveries are made. Your market access strategies must evolve too.

Topic Cancer Drug Development Landscape Reimbursement

View infographic
Scrip

Sanofi's €10bn Dupixent Plan: 'We're Going To Put The JAKs Properly In Their Place'

By Jessica Merrill 14 Nov 2022

Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.

Topic Business Strategies Immune Disorders Inflammation

View article
In Vivo

Critical Insights into Market Access

14 Nov 2022

Your key to refining your market access strategy with essential patient market access mini-mag and infographic from the experts at In Vivo.

View infographic
In Vivo

From US To EU: Young Biotechs Going It Alone

By Jo Shorthouse 14 Nov 2022

Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.

Topic Market Access Rare Diseases Strategy

View analysis
Scrip

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

By Mandy Jackson 14 Nov 2022

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Topic Cell & Gene Therapy Drug Development Landscape

View article
Datamonitor Healthcare

Acute Myeloid Leukemia Market Outlook Seminar

By Dominique Fontanilla 14 Nov 2022

There has been little change to standard treatment for AML in recent years; however, 2017 saw a flurry of new targeted drug approvals, sparking significant market growth. Patient age remains the biggest factor in driving treatment decisions for AML. Cases of AML are expected to increase, and prognosis remains poor – especially among older adults. Drug developers are targeting patient segments with high unmet clinical need to gain access to the AML market and the budget impact of AML is expected to grow considerably.

Topic Cancer

Full video
Datamonitor Healthcare

Understand Market Access Trends in the US, Europe and Emerging Markets

14 Nov 2022

This essential whitepaper looks at how increased drug spending and a rising desire for expenditure controls are influencing access dynamics across key markets. It is available to you now, for free.

Topic Drug Development Landscape Approvals Drug Review

View white paper

Latest headlines

HBW Insight

29 Mar 2023

Germany's Dermapharm Looks To Future With Arkopharma As 2022 Sales Rise

Link
Generics Bulletin

29 Mar 2023

Teva Moves Ahead With Digital Respiratory Initiative

Link
Medtech Insight

29 Mar 2023

Why Adding A Legacy Device To Eudamed Now, Before It is Mandatory, Is A Shrewd Move

Link
Scrip

29 Mar 2023

Banking Crisis Prompts Postponed Noile-Immune IPO, But Wider Japan Views Mixed

Link
Scrip

28 Mar 2023

Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy

Link
Scrip

28 Mar 2023

Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy

Link
Scrip

28 Mar 2023

Path Ahead For Neuraly’s NLY01 Unclear After Phase II Parkinson’s Disappointment

Link
Scrip

28 Mar 2023

Pipeline Watch - ADD Meeting Dominates Phase III Readouts

Link
Scrip

28 Mar 2023

Pipeline Watch - ADD Meeting Dominates Phase III Readouts

Link
Scrip

28 Mar 2023

Path Ahead For Neuraly’s NLY01 Unclear After Phase II Parkinson’s Disappointment

Link
Scrip

28 Mar 2023

Big Pharma CEOs Suggest Policy Changes As They Return To Beijing

Link
HBW Insight

28 Mar 2023

For First US OTC Birth Control Application, FDA Extends Time For Advisory Panel Discussion

Link
Pink Sheet

28 Mar 2023

Shared Savings Legislation Could Increase Medicare Biosimilar Access

Link
Pink Sheet

28 Mar 2023

Positive Feelings About Negative Controls: US FDA Explores Another Tool For The Real-World Evidence Toolbox

Link
Pink Sheet

28 Mar 2023

Game On: Medicare Will Parry Manufacturer Efforts To Sidestep Price Negotiation, Guidance Says

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Speak to Sales

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact Sales

Client Services

US Toll-Free : +1 888 670 8900
US Toll : +1 212-600-3520
UK & Europe : +44 (0) 208 052 0700

Contact Customer Services

Pharma Report Store

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now

Tailor-made Pharma Solutions

Tailor-made solutions

Pharma Intelligence latest insights

Opdivos EU Colorectal Cancer is a Setback but More Than Offset By Potential Gains

AstraZeneca takes an innovative approach to trial results summaries

Trial results transparency starts here

2020 Clinical Trials Roundup: Disruptions to the Trial Landscape

5 Top Tips For Generating Successful Content Marketing

Bayer’s US Playbook: The Smart Way To Top-Line Growth

Inside Toyota's 'Cult' Car-Makers Quality VP Tells Device-Makers How To Adopt 4-Pronged Quality Strategy

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

Multiple Myeloma Pricing, Reimbursement, and Access

Sanofi's €10bn Dupixent Plan: 'We're Going To Put The JAKs Properly In Their Place'

Critical Insights into Market Access

From US To EU: Young Biotechs Going It Alone

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

Acute Myeloid Leukemia Market Outlook Seminar

Understand Market Access Trends in the US, Europe and Emerging Markets

Latest headlines

Germany's Dermapharm Looks To Future With Arkopharma As 2022 Sales Rise

Teva Moves Ahead With Digital Respiratory Initiative

Why Adding A Legacy Device To Eudamed Now, Before It is Mandatory, Is A Shrewd Move

Banking Crisis Prompts Postponed Noile-Immune IPO, But Wider Japan Views Mixed

Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy

Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy

Path Ahead For Neuraly’s NLY01 Unclear After Phase II Parkinson’s Disappointment

Pipeline Watch - ADD Meeting Dominates Phase III Readouts

Pipeline Watch - ADD Meeting Dominates Phase III Readouts

Path Ahead For Neuraly’s NLY01 Unclear After Phase II Parkinson’s Disappointment

Big Pharma CEOs Suggest Policy Changes As They Return To Beijing

For First US OTC Birth Control Application, FDA Extends Time For Advisory Panel Discussion

Shared Savings Legislation Could Increase Medicare Biosimilar Access

Positive Feelings About Negative Controls: US FDA Explores Another Tool For The Real-World Evidence Toolbox

Game On: Medicare Will Parry Manufacturer Efforts To Sidestep Price Negotiation, Guidance Says

Next steps

This is Contactus Section

Request a live demo

Speak to Sales

Client Services

Pharma Report Store